Planet MicroCap Showcase: Toronto 2026
Logotype for PharmaCorp Rx Inc

PharmaCorp Rx (PCRX) Planet MicroCap Showcase: Toronto 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for PharmaCorp Rx Inc

Planet MicroCap Showcase: Toronto 2026 summary

8 Nov, 2026

Acquisition strategy and pipeline

  • PharmaChoice alliance provides exclusive ROFRs on 1,150 stores; McKesson collaboration adds opportunities across IDA, Guardian and Remedy'sRx when McKesson does not pursue a store.

  • Management cited access to 3,000+ stores across the networks, with 30-50 PharmaChoice and 50-80 McKesson locations changing hands annually; banner-agnostic deal selection.

  • 17 locations in the portfolio; an eight-store East Coast acquisition closed for CAD 24 million in July and is being integrated; two LOIs represent four stores.

  • Target acquisitions with at least CAD 2 million revenue and CAD 350,000 normalized EBITDA; weighted-average purchase multiple is 6x normalized EBITDA.

Acquisition diligence and growth

  • Evaluate each deal on normalized economics, prescription trends, staffing and managing-pharmacist coverage; willing to walk away from stores that cannot be staffed.

  • Project cumulative normalized EBITDA gains of 7.5%-15% over the first three years of ownership; management clarified this is cumulative, not annual CAGR.

  • Value creation includes purchasing efficiencies, network programs, expanded pharmacist services and automation; one purchasing change added CAD 80,000 in store profitability in one year.

  • Two smaller pharmacies were acquired and folded into existing stores in the prior year; one example combined a 10,000-prescription store with a 70,000-prescription location.

  • Acquired stores remain under their existing banners to preserve customer and staff continuity; planned store improvements can include rebranding, automation and expansion, including a planned doubling of one store early next year.

Ownership model and cash generation

  • Co-ownership loans let pharmacists buy in alongside the operator; 16 of 17 stores are expected to have a co-owner, including two where sellers retained 10% and 25% stakes.

  • CIBC acquisition term loan was initially CAD 17.5 million and upsized to CAD 27.5 million through an accordion; management cited ample capacity for current LOIs.

  • Target leverage is 2.0-2.5x as a high-water mark; funding options may include the market when conditions are attractive, alongside scaling debt for individual deals.

  • Maintenance CapEx is 20-40 bps of sales and EBITDA-to-free-cash-flow conversion exceeds 70%; a CAD 300,000 automation robot had a stated payback of 2.5 years.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from PharmaCorp Rx